WallStreetZenWallStreetZen

NASDAQ: HZNP
Horizon Therapeutics Public Ltd Co Stock

$109.68-0.11 (-0.1%)
Updated Feb 3, 2023
HZNP Price
$109.68
Fair Value Price
$118.73
Market Cap
$24.86B
52 Week Low
$57.84
52 Week High
$117.49
P/E
43.7x
P/B
4.94x
P/S
3.85x
PEG
0.95x
Dividend Yield
N/A
Revenue
$3.70B
Earnings
$574.26M
Gross Margin
75.1%
Operating Margin
18.12%
Profit Margin
15.5%
Debt to Equity
0.79
Operating Cash Flow
$1B
Beta
0.87
Next Earnings
Mar 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A

HZNP Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Zen Score

Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HZNP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HZNP ($109.68) is undervalued by 7.62% relative to our estimate of its Fair Value price of $118.73 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HZNP ($109.68) is not significantly undervalued (7.62%) relative to our estimate of its Fair Value price of $118.73 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HZNP ($109.68) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HZNP due diligence checks available for Premium users.

Be the first to know about important HZNP news, forecast changes, insider trades & much more!

HZNP News

Valuation

HZNP fair value

Fair Value of HZNP stock based on Discounted Cash Flow (DCF)
Price
$109.68
Fair Value
$118.73
Undervalued by
7.62%
HZNP ($109.68) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HZNP ($109.68) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HZNP ($109.68) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HZNP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
43.7x
Industry
30.81x
Market
15.09x
HZNP is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HZNP is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

HZNP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.94x
Industry
5.14x
HZNP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HZNP price to earnings growth (PEG)

For valuing profitable companies with growth potential
HZNP is good value based... subscribe to Premium to read more.
PEG Value Valuation

HZNP's financial health

Profit margin

Revenue
$925.4M
Net Income
$135.8M
Profit Margin
14.7%
HZNP's Earnings (EBIT) of $670.85M... subscribe to Premium to read more.
Interest Coverage Financials
HZNP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$9.0B
Liabilities
$4.0B
Debt to equity
0.79
HZNP's short-term assets ($3.41B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HZNP's short-term assets ($3.41B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HZNP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HZNP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$366.5M
Investing
-$32.0M
Financing
-$94.4M
HZNP's operating cash flow ($1.37B)... subscribe to Premium to read more.
Debt Coverage Financials

HZNP vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
HZNP$24.86B-0.10%43.70x4.94x
BIIB$40.84B-1.35%14.41x3.20x
OGN$7.57B-2.14%7.48x-7.10x
GRFS$6.67B+0.83%31.91x1.11x
TSVT$535.76M+1.00%N/A1.66x

Horizon Therapeutics Public Co Stock FAQ

What is Horizon Therapeutics Public Co's quote symbol?

NASDAQ: HZNP) Horizon Therapeutics Public Co trades on the NASDAQ under the ticker symbol HZNP. Horizon Therapeutics Public Co stock quotes can also be displayed as NASDAQ: HZNP.

If you're new to stock investing, here's how to buy Horizon Therapeutics Public Co stock.

What is the 52 week high and low for Horizon Therapeutics Public Co (NASDAQ: HZNP)?

(NASDAQ: HZNP) Horizon Therapeutics Public Co's 52-week high was $117.49, and its 52-week low was $57.84. It is currently -6.65% from its 52-week high and 89.63% from its 52-week low.

How much is Horizon Therapeutics Public Co stock worth today?

(NASDAQ: HZNP) Horizon Therapeutics Public Co currently has 226,621,465 outstanding shares. With Horizon Therapeutics Public Co stock trading at $109.68 per share, the total value of Horizon Therapeutics Public Co stock (market capitalization) is $24.86B.

Horizon Therapeutics Public Co stock was originally listed at a price of $9.15 in Jul 28, 2011. If you had invested in Horizon Therapeutics Public Co stock at $9.15, your return over the last 11 years would have been 1,098.69%, for an annualized return of 25.33% (not including any dividends or dividend reinvestments).

How much is Horizon Therapeutics Public Co's stock price per share?

(NASDAQ: HZNP) Horizon Therapeutics Public Co stock price per share is $109.68 today (as of Feb 3, 2023).

What is Horizon Therapeutics Public Co's Market Cap?

(NASDAQ: HZNP) Horizon Therapeutics Public Co's market cap is $24.86B, as of Feb 5, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Horizon Therapeutics Public Co's market cap is calculated by multiplying HZNP's current stock price of $109.68 by HZNP's total outstanding shares of 226,621,465.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.